Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verastem (VSTM) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for Verastem (VSTM) over the last 8 years, with Q3 2025 value amounting to $137.7 million.

  • Verastem's Cash & Equivalents rose 2167.53% to $137.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.7 million, marking a year-over-year increase of 2167.53%. This contributed to the annual value of $88.8 million for FY2024, which is N/A changed from last year.
  • Per Verastem's latest filing, its Cash & Equivalents stood at $137.7 million for Q3 2025, which was up 2167.53% from $164.3 million recorded in Q2 2025.
  • In the past 5 years, Verastem's Cash & Equivalents registered a high of $183.1 million during Q2 2023, and its lowest value of $24.3 million during Q3 2021.
  • Moreover, its 5-year median value for Cash & Equivalents was $82.3 million (2024), whereas its average is $88.3 million.
  • As far as peak fluctuations go, Verastem's Cash & Equivalents plummeted by 8573.71% in 2021, and later surged by 22148.56% in 2022.
  • Quarter analysis of 5 years shows Verastem's Cash & Equivalents stood at $74.8 million in 2021, then grew by 5.73% to $79.1 million in 2022, then increased by 20.12% to $95.0 million in 2023, then fell by 6.49% to $88.8 million in 2024, then soared by 55.04% to $137.7 million in 2025.
  • Its Cash & Equivalents stands at $137.7 million for Q3 2025, versus $164.3 million for Q2 2025 and $117.6 million for Q1 2025.